Today News Journal
    What's Hot

    Fake Meat’s Beyond Impossible Quest to Win Over Americans

    February 5, 2023

    Here’s How Finland, Sweden and NATO Should Deal With Erdogan

    February 5, 2023

    What Europe Risks With Wider Sanctions on Russian Oil

    February 5, 2023
    Facebook Twitter Instagram
    Facebook Twitter Instagram
    Today News Journal
    Contact Us
    • Home
    • Trending
    • Business
    • Health
    • Technology
      • Automobile
      • Gadgets
      • Mobiles
      • Robotics
    • Lifestyle
      • Culture
    • Sports
    • Travel
    • Editorials
    • News
      • Politics
    Today News Journal
    Home » Health » Lecanemab: FDA decision on experimental Alzheimer’s drug expected this week
    Health

    Lecanemab: FDA decision on experimental Alzheimer’s drug expected this week

    James MartinBy James MartinJanuary 5, 2023No Comments5 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp VKontakte Email
    Share
    Facebook Twitter LinkedIn Pinterest Email





    CNN
     — 

    The US Food and Drug Administration could decide this week whether to grant accelerated approval to the experimental dementia drug lecanemab, according to Eisai and Biogen, the companies that make the drug.

    Lecanemab – one of the first experimental dementia drugs to appear to slow the progression of cognitive decline – has shown “potential” as an Alzheimer’s disease treatment, according to Phase 3 trial results, but raised safety concerns due to its association with certain serious adverse events, including brain swelling and bleeding.

    In July, the FDA accepted Eisai’s Biologics License Application for lecanemab under the accelerated approval pathway and granted the drug priority review, according to the company. The accelerated approval program allows for earlier approval of drugs that treat serious conditions and “fill an unmet medical need” while the drugs continue to be studied in larger and longer trials.

    The FDA is expected to decide whether to grant accelerated approval to lecanemab by January 6, Eisai spokesperson Libby Holman confirmed to CNN.

    “If lecanemab is approved by the FDA under the Accelerated Approval Pathway, Eisai will do its best to make lecanemab available as soon as possible,” Holman wrote in an email. “Eisai aims to file a Supplemental Biologics License Application for traditional approval in the U.S. soon and to file marketing authorization applications in Japan and Europe by the end of Eisai’s fiscal year 2022, which ends on March 31, 2023.”

    The Alzheimer’s Association also expects the FDA to take action by January 6, Maria Carrillo, the group’s chief science officer, said in a statement.

    “We believe, based on the totality of positive data from clinical trials of this treatment, that the FDA should approve. Peer-reviewed, published results show lecanemab will provide patients in the earliest stages of Alzheimer’s more time to participate in daily life and live independently. It could mean many months more of recognizing their spouse, children and grandchildren,” Carrillo said in the statement.

    She added that the Alzheimer’s Association hopes that the Centers for Medicare and Medicaid Services “will move quickly” to cover the drug and “revise its coverage decision that currently blocks access to this treatment.” CMS determines whether to cover FDA-approved therapies based on whether it deems them to be safe and effective.

    “The Alzheimer’s Association has filed a formal request asking CMS to provide full and unrestricted coverage for FDA-approved Alzheimer’s treatments,” Carrillo said.

    Lecanemab, a monoclonal antibody, is not a cure, but works by binding to amyloid beta, a hallmark of Alzheimer’s disease.

    In late November, results from an 18-month Phase 3 clinical trial published in The New England Journal of Medicine showed that lecanemab “reduced markers of amyloid in early Alzheimer’s disease and resulted in moderately less decline on measures of cognition and function than placebo at 18 months but was associated with adverse events.”

    The results also showed that about 6.9% of the trial participants given lecanemab, as an intravenous infusion, discontinued the trial due to adverse events, compared with 2.9% of those given a placebo. Overall, there were serious adverse events in 14% of the lecanemab group and 11.3% of the placebo group.

    The most common adverse events in the lecanemab group were reactions to the intravenous infusions and abnormalities on their MRIs, such as brain swelling and bleeding called amyloid-related imaging abnormalities, or ARIA, which can become life threatening.

    Some people who get ARIA may not have symptoms, but it can occasionally lead to hospitalization or lasting impairment. And the frequency of ARIA appeared to be higher in people who had a gene called APOE4, which can increase the risk of Alzheimer’s disease and other dementias. ARIA “were numerically less common” among APOE4 noncarriers.

    The trial results also showed that about 0.7% of participants in the lecanemab group and 0.8% of those in the placebo group died, corresponding to six deaths in the lecanemab group and seven in the placebo group.

    Even if the FDA offers accelerated approval of the drug, it will still be studied in more robust trials. And if those trials confirm that the drug provides a clinical benefit, the FDA could grant traditional approval. But if the confirmatory trial does not show benefit, the FDA has regulatory procedures that could lead to taking the drug off the market.

    “If and when this drug is approved by the FDA, it will take clinicians some time to be able to parse out how this drug may or may not be effective in their own individual patients,” especially since carriers of the APOE4 gene could be at higher risk of side effects, Dr. Richard Isaacson, director of the Alzheimer’s Prevention Clinic in the Center for Brain Health at Florida Atlantic University’s Schmidt College of Medicine, who is not involved in studying lecanemab or its development, said in November.

    More than 300 Alzheimer’s treatments are in clinical trials, according to the Alzheimer’s Association. Alzheimer’s disease was first documented in 1906, when Dr. Alois Alzheimer discovered changes in the brain tissue of a woman who had memory loss, language problems and unpredictable behaviors.

    The debilitating disease affects more than 6 million adults in the United States.



    Source link

    Related posts:

    1. Tracking Covid-19 cases in the US
    2. Covid-19 case rates still matter
    3. New versions of Omicron variant make gains against BA.2
    4. Covid-19 Pandemic Timeline Fast Facts
    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Previous ArticleWatch Samsung’s keynote at CES 2023 in 6 minutes
    Next Article Keir Starmer to promise ‘completely new way of governing’ in major speech – UK politics live | Politics
    James Martin
    • Website

    Related Posts

    How to be prepared in case of a shooting without living in fear

    January 26, 2023

    Many women underestimate breast density as a risk factor for breast cancer, study shows

    January 26, 2023

    Pediatricians are giving out free gun locks to approach the gun violence epidemic as a public health crisis

    January 25, 2023

    CDC figuring out ‘logistical and legal’ aspects of testing airplane wastewater for coronavirus variants, source says

    January 25, 2023

    Leave A Reply Cancel Reply

    Search
    Categories
    • Automobile
    • Business
    • Coronavirus
    • Culture
    • Editorials
    • Finance
    • Gadgets
    • Health
    • Lifestyle
    • Mobiles
    • Money
    • News
    • Politics
    • Sports
    • Technology
    • Travel
    • Trending
    • World
    Latest Posts

    Fake Meat’s Beyond Impossible Quest to Win Over Americans

    February 5, 2023

    Here’s How Finland, Sweden and NATO Should Deal With Erdogan

    February 5, 2023

    What Europe Risks With Wider Sanctions on Russian Oil

    February 5, 2023

    Why Pakistan Is Struggling to Get Another IMF Bailout

    February 5, 2023
    • Facebook
    • Twitter
    Don't Miss
    News

    Fake Meat’s Beyond Impossible Quest to Win Over Americans

    By James MartinFebruary 5, 20230

    Comment on this storyCommentNot so long ago, alternative protein products like Beyond Meat and Impossible…

    Here’s How Finland, Sweden and NATO Should Deal With Erdogan

    February 5, 2023

    What Europe Risks With Wider Sanctions on Russian Oil

    February 5, 2023

    Why Pakistan Is Struggling to Get Another IMF Bailout

    February 5, 2023
    • Facebook
    • Twitter
    About Us

    Hello friends, I am James Martin. Welcome to my blog todaynewsjournal.com. We are a team of experienced journalists who are passionate about delivering the latest news and current events to our readers. Our editorial team is dedicated to providing the most accurate and up-to-date information possible. We aim to be your go-to source for news and current events. Here on this site, You will get up to date information regarding all important categories like business ideas, health tips,... (Read More)

    Latest News

    Fake Meat’s Beyond Impossible Quest to Win Over Americans

    February 5, 2023

    Here’s How Finland, Sweden and NATO Should Deal With Erdogan

    February 5, 2023

    What Europe Risks With Wider Sanctions on Russian Oil

    February 5, 2023
    SIGN UP NEWSLETTER

    Join The Conversation sign up to receive emails for The Daily special tips general info.

      Facebook Twitter Instagram Pinterest
      • Home
      • Editorials
      • Get In Touch

      Copyright © 2021-2023 · Today News Journal Privacy Policy

      Type above and press Enter to search. Press Esc to cancel.

      We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
      Cookie SettingsAccept All
      Manage consent

      Privacy Overview

      This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
      Necessary
      Always Enabled
      Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
      CookieDurationDescription
      cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
      cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
      cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
      cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
      cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
      viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
      Functional
      Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
      Performance
      Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
      Analytics
      Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
      Advertisement
      Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
      Others
      Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
      SAVE & ACCEPT

      Sign In or Register

      Welcome Back!

      Login to your account below.

      Lost password?